News
FDA approves first treatment for primary HLH
The U.S.
News
Triplet produces ‘unprecedented’ ORR in PI-refractory MM
Phase 2 results suggest a three-drug regimen may improve response rates in patients with proteasome inhibitor (PI)-refractory multiple myeloma (MM...
News
Education can improve adherence to VTE prophylaxis
Education can improve adherence to venous thromboembolism (VTE) prophylaxis among hospitalized patients, according to researchers. They assessed...
News
Score can predict thrombosis in ITP
New research suggests a scoring system can predict the risk of thrombosis in patients with immune thrombocytopenia (ITP) who are taking...
News
‘Encouraging’ phase 2 results in rel/ref AML
The combination of azacitidine and nivolumab produced “encouraging” results in a phase 2 trial of patients with relapsed or refractory acute...
News
FDA approves elotuzumab combo for rel/ref MM
The U.S.
News
Underused PV treatments save lives, doc says
Researchers have found evidence to suggest that phlebotomy and hydroxyurea (HU) provide real-world benefits for older patients with polycythemia...
News
Denosumab fights osteoporosis in TDT patients
Denosumab can be effective against osteoporosis caused by transfusion-dependent thalassemia (TDT), according to research published in Blood...
News
Novel risk factors for febrile neutropenia in NHL, other cancers
A retrospective study has revealed new potential risk factors for chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors and...
News
Understanding the role of HSCT in PTCL
DUBROVNIK, CROATIA—Hematopoietic stem cell transplant (HSCT) can be hit-or-miss in patients with peripheral T-cell lymphomas (PTCLs), according to...
News
FDA issues draft guidance on MRD
The U.S.
News
Questions surround MRD assessment in MM
DUBROVNIK, CROATIA—Clinical trials are needed to answer the many questions related to minimal residual disease (MRD) assessment in multiple...
News
The challenges of diagnosing CMML
DUBROVNIK, CROATIA—Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and...
News
Optimizing use of TKIs in CML
DUBROVNIK, CROATIA—Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (...
News
CDK8 inhibitor can fight AML, though it’s unclear how
DUBROVNIK, CROATIA—The CDK8 inhibitor SEL120 has demonstrated preclinical activity against acute myeloid leukemia (AML), but the agent’s mechanism...